Deutsche Bank Ag\ Instil Bio, Inc. Transaction History

Deutsche Bank Ag\

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$0.4 - $0.63 $3,986 - $6,278	-9,966 Reduced 61.66%	6,197 $2,000
Q2 2023 Aug 14, 2023	SELL	$0.51 - $0.67 $29,300 - $38,492	-57,452 Reduced 78.04%	16,163 $8,000
Q1 2023 May 15, 2023	BUY	$0.6 - $0.91 $24,858 - $37,702	41,431 Added 128.73%	73,615 $48,000
Q4 2022 Feb 13, 2023	SELL	$0.48 - $5.33 $7,412 - $82,305	-15,442 Reduced 32.42%	32,184 $20,000
Q3 2022 Nov 14, 2022	BUY	$4.65 - $7.37 $68,471 - $108,523	14,725 Added 44.76%	47,626 $231,000
Q2 2022 Aug 11, 2022	BUY	$4.21 - $11.15 $11,181 - $29,614	2,656 Added 8.78%	32,901 $152,000
Q1 2022 May 13, 2022	SELL	$8.48 - $18.1 $29,510 - $62,988	-3,480 Reduced 10.32%	30,245 $325,000
Q4 2021 Feb 11, 2022	BUY	$15.37 - $22.5 $360,657 - $527,962	23,465 Added 228.7%	33,725 $577,000
Q3 2021 Nov 04, 2021	SELL	$15.05 - $23.28 $1,339 - $2,071	-89 Reduced 0.86%	10,260 $183,000
Q2 2021 Aug 11, 2021	BUY	$15.31 - $24.63 $158,443 - $254,895	10,349 New	10,349 $200,000

1.9M

Ticker TIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,694,000
Market Cap $2.84B
Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small ce...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.